Vor Biopharma Inc reports results for the quarter ended in December - Earnings Summary

Vor Biopharma

21/03/2024 12:01

* Vor Biopharma Inc  VOR.OQ  reported a quarterly adjusted
loss
of 39 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -52 cents.  The mean expectation of
nine analysts for the quarter was for a loss of 50 cents per
share. Wall Street expected results to range from -53 cents
to -46 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Vor Biopharma Inc's reported EPS for the quarter was a
loss
of 39 cents​.
    * The company reported a quarterly loss of $26.26 million.
    * Vor Biopharma Inc shares had fallen by 20.0% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Vor
Biopharma Inc
is $13.50 

This summary was machine generated from LSEG data March 21 at
12:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.50          -0.39          Beat
 Sep. 30 2023      -0.47          -0.49          Missed
 Jun. 30 2023      -0.43          -0.45          Missed
 Mar. 31 2023      -0.38          -0.43          Missed